A phase 1, first-in-human, dose-escalation and expansion study of FX-909 in patients with advanced solid malignancies, including advanced urothelial carcinoma.

Gopa Iyer, Matt D. Galsky, Drew Rasco et al.|Journal of Clinical Oncology|2024

Cited by 5